

Joint Event on 2nd World Congress on
Infectious Diseases

&

International Conference on

Pediatric Care & Pediatric Infectious Diseases

August 24-26, 2016 Philadelphia, USA



Glenn S Tillotson

Cempra Pharmaceuticals, USA

The burden of antibiotic resistance

Antimicrobial resistance (AMR) is an escalating problem globally. The consequences of resistance may include increased morbidity and mortality. However the economic impact of this problem is poorly understood. In addition to enormous human cost of AMR there have been attempts to estimate the economic costs as well. These would be either direct healthcare costs such as increased length of hospital stays, loss of productivity or secondary social costs such as foregoing medical procedures or refraining from travel because of increased risk. In 2013, the CDC estimated that the direct costs of AMR were US \$20 billion with additional productivity losses of US \$35 billion. The CDC has also published a list of bacterial species in which antibiotic resistance has reached significant levels. The impact of antibiotic resistance in five species will be discussed namely; *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Streptococcus pneumoniae*. The global implications of antibiotic resistance will be put into perspective.

Biography

Glenn S Tillotson has over 30 years pharmaceutical experience in pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management and global launch programs. He has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin, fidaxomicin and several other agents. He is a SVP of Medical Affairs where he is preparing for the launch of solithromycin for community acquired bacterial pneumonia. He has published more than 170 peer-reviewed manuscripts and is on several journal Editorial Advisory Boards including the *Lancet Infectious Disease*, *eBioMedicine*, *Expert Reviews in Anti-infective Therapy* and *F1000*.

gtillotson@cempra.com

Notes: